Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AbSci (ABSI – Research Report), Soleno Therapeutics (SLNO – Research Report) and I-MAB (IMAB – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

AbSci (ABSI)

In a report released today, Brian Cheng from J.P. Morgan initiated coverage with a Buy rating on AbSci. The company’s shares closed last Wednesday at $3.13, close to its 52-week low of $2.45.

According to TipRanks.com, Cheng has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -14.1% and a 39.9% success rate. Cheng covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Crispr Therapeutics AG, and Allogene Therapeutics. ;'>

AbSci has an analyst consensus of Strong Buy, with a price target consensus of $7.22.

See the top stocks recommended by analysts >>

Soleno Therapeutics (SLNO)

Stifel Nicolaus analyst James Condulis maintained a Buy rating on Soleno Therapeutics yesterday and set a price target of $115.00. The company’s shares closed last Wednesday at $60.12.

According to TipRanks.com, Condulis is a 2-star analyst with an average return of 5.6% and a 61.5% success rate. Condulis covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., Mirum Pharmaceuticals, and Cytokinetics. ;'>

Currently, the analyst consensus on Soleno Therapeutics is a Strong Buy with an average price target of $119.60, a 79.6% upside from current levels. In a report issued on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $110.00 price target.

I-MAB (IMAB)

BTIG analyst Justin Zelin initiated coverage with a Buy rating on I-MAB yesterday and set a price target of $7.00. The company’s shares closed last Wednesday at $3.86.

According to TipRanks.com, Zelin is a 3-star analyst with an average return of 3.3% and a 34.5% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Janux Therapeutics Inc, and Mersana Therapeutics. ;'>

Currently, the analyst consensus on I-MAB is a Strong Buy with an average price target of $7.00, implying an 89.7% upside from current levels. In a report issued on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.

Read More on ABSI:

Disclaimer & DisclosureReport an Issue

• Absci announces collaboration with Oracle Cloud Infrastructure, AMD
• Absci Corp. Earnings Call: Strategic Gains Amid Challenges
• Promising Potential of AbSci’s ABS-201 Therapy for Androgenetic Alopecia: A Buy Recommendation
• Promising Developments and Strong Financial Position Bolster AbSci’s Growth Prospects
• AbSci’s Positive Outlook: Strong Financial Position and Promising ABS-101 Developments Support Buy Rating